CR-CP leads $44m series-C for ReViral

In February 2019, China Resources Holdings, a China-Hong Kong state-owned multi-sector conglomerate, joined Charoen Pokphand Group of Bangkok, a Thai conglomerate, to launch the $300m CR-CP Life Science Fund. The two general partners provided a combined $150m and the fund raised another $150m from global LPs. The fund invests in companies that develop drugs and cell therapies, medical devices and healthcare artificial intelligence.

Additional investors participating in the latest round included Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors and Perceptive Advisors.

The proceeds will be used to support phase-II clinical development for Sisunatovir, the company's wholly-owned fusion protein inhibitor.

Jason Zhou, CEO and managing director of CR-CP Life Science Fund, joins the ReViral board of directors.

Previous funding
Undisclosed investors provided $1m to ReViral in December 2014.

In 2015, Andera and OrbiMed led a $21m round for the company.

Company
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing and commercialising novel antiviral therapeutics that target respiratory syncytial virus. Based in Stevenage, the company was founded in 2011 and employs 18 people.

People
CR-CP Life Science Fund – Jason Zhou (CEO, managing director).
ReViral – Alex Sapir (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture